Explore the clinical trial results for XHANCE

XHANCE was studied in two Phase 3 pivotal trials and two Phase 3 open-label trials1-4

XHANCE was evaluated in NAVIGATE I and NAVIGATE II: Two similar Phase 3 pivotal randomized, placebo-controlled multicenter studies (N=646).1,3

Learn more

Improvement in congestion and other defining nasal symptoms

Patients using XHANCE reported improvement in congestion (coprimary endpoint) and the other 3 defining nasal symptoms.1,3

Learn more

Reductions in bilateral polyp grade

XHANCE reduced bilateral polyp grade (coprimary endpoint), with up to 28% of patients achieving total polyp elimination.1,3

Learn more

~90% of patients using XHANCE reported overall improvement2

Two-thirds of patients reported a Patient Global Impression of Change (PGIC) of “much improved” or “very much improved.”3

Learn more

Exhalation helps deliver medication high and deep into the nasal passages.1,2

  1. Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2017.
  2. Data on file. OptiNose US, Inc.
  3. Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized double-blind trial of the exhalation delivery system with fluticasone (EDS-FLU) for nasal polyposis. J Allergy Clin Immunol. 2018; In press.
  4. Palmer JN, Jacobson KW, Messina JC, Kosik-Gonzalez C, Djupesland PG, Mahmoud RA. EXHANCE-12: 1-year study of the exhalation delivery system with fluticasone (EDS-FLU) in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2018; In press.